Migraine sufferers will soon have Vyepti—another option to treat their chronic, debilitating headaches—and it’s the first of its kind.

Vyepti Intraveneous migraine prevention - The Headache CenterThe FDA-approved Vyepti, which should be available in April, is the first-ever intravenous calcitonin gene-related peptide blocker for migraine prevention in adults.

The IV drug therapy “achieves the key treatment goal of preventing migraine over time while also delivering on the need for earlier onset of efficacy,” said Dr. Deborah Dunsire, president and CEO of Lundbeck, a pharmaceutical company that specializes in brain diseases. “The VYEPTI clinical program is the first to demonstrate this early benefit.”

Vyepti offers unique benefits for the 39 million Americans suffering from migraine, said Dr. Roger Cady, vice president of neurology at Lundbeck. The generic name for the drug is eptinezumab-jjmr.

 “First, no other approved preventive CGRP therapy has clinical data in their label showing effect before 30 days and in some cases three months or longer,” Cady said. “Second, eptinezumab-jjmr was developed for administration by IV infusion to deliver 100 percent of the medication quickly into the bloodstream, so it can start to work as soon as possible after administration.”

Other CGRP blockers take two to seven days to take effect, Dr. Stewart J. Tepper, a professor of neurology at Dartmouth Geisel School of Medicine who supervised some of those eptinezumab-jjmr trials, said in a Healio Primary Care blog.

Vypeti - migraine prevention - The Headache CenterThe drug was studied in two clinical trials, for both episodic and chronic migraines, according to the Lundbeck website. Benefits were noted as early as one day after the first infusion.

The data from the second trial, which focused on chronic migraine, “showed that many patients can achieve reduction in migraine days of at least 75 percent and experience a sustained migraine improvement through six months, which is clinically meaningful to both physicians and patients,” said Dr. Peter Goadsby, a professor of neurology at King’s College, London and the University of California, San Francisco. “VYEPTI is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”

Though the cost of the drug treatment has not yet been disclosed, it should be less than $10,000 annually, before discounts, Dr. Stephen D. Silberstein, director of the Headache Center at Jefferson Health in Philadelphia, said in the same Healio blog. Silberstein said that it is a reasonable price.

“The World Health Organization has called migraine a major disorder that is associated with disability,” Silberstein said. “A patient with migraine is more disabled than someone who is paralyzed in their arms and legs.”

To read more about Vyepti, clinical trials, and adverse reactions, visit the Lundbeck site.

Suffering from chronic or episodic migraine? Have frequent headaches you can’t identify? Get in touch for an appointment now; the Headache Center does not require a physician’s referral.